NCT07506356 Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors
| NCT ID | NCT07506356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Diabete Type 2 |
| Study Type | OBSERVATIONAL |
| Enrollment | 38 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 38 participants in total. It began in 2026-04-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach. This is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days. To recruit the necessary number of participants, approximately 1.5 years will be needed. This project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project. The project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and/or cereals and/or proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam. At 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.
Eligibility Criteria
Inclusion Criteria: * Female/ Male of 18 years old or more * With Type 2 Diabetes * Treated with GLP 1 analog for more than 3 months * Signed consent * ASA between I and IV Exclusion Criteria: * Insuline treatment * Gastro intestinal motility disorders * Past gastric surgery * Hiatal hernia * Recent trauma * Inability to be lay down for the exam * Inability to follow the instructions for the exam (language, dementia) * BMI \> 40 * Inability to stop smoking 12h before the measures
Frequently Asked Questions
Who can join the NCT07506356 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabete Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07506356 currently recruiting?
Yes, NCT07506356 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Geneva to inquire about joining.
Where is the NCT07506356 trial being conducted?
This trial is being conducted at Geneva, Switzerland.
Who is sponsoring the NCT07506356 clinical trial?
NCT07506356 is sponsored by University Hospital, Geneva. The trial plans to enroll 38 participants.